Evidence map›Paper›PMID 36596665›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2023

Benign Breast Disease, NSAIDs, and Postmenopausal Breast Cancer Risk in the CPS-II Cohort.

Mark E Sherman, Robert A Vierkant, Matthew Masters, Derek C Radisky, Stacey J Winham, Amy C Degnim, Celine M Vachon, Alpa V Patel, Lauren R Teras

Open access · bronzeAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Mark E Sherman *Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0002-9222-8808
Robert A Vierkant *Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-6242-5221
Matthew MastersBehavioral and Epidemiology Research Program, American Cancer Society, Atlanta, Georgia.ORCID 0000-0002-7245-8630
Derek C RadiskyDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0002-1962-8784
Stacey J WinhamQuantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-8492-9102
Amy C DegnimDepartment of Surgery, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-2303-4946
Celine M VachonDivision of Epidemiology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-1962-9322
Alpa V PatelBehavioral and Epidemiology Research Program, American Cancer Society, Atlanta, Georgia.ORCID 0000-0001-9997-1218
Lauren R TerasBehavioral and Epidemiology Research Program, American Cancer Society, Atlanta, Georgia.ORCID 0000-0003-2419-8536
American Cancer Society · USJacksonville College · USMayo Clinic · USMayo Clinic in Florida · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Predicting Breast Cancer Risk after Benign Percutaneous BiopsyR01CA229811 · NCI · MAYO CLINIC JACKSONVILLE · PI DEGNIM, AMY C, SHERMAN, MARK E · 2018 to 2022
$3.5M
Involution-based biomarkers of breast cancer riskR01CA237602 · NCI · MAYO CLINIC JACKSONVILLE · PI DEGNIM, AMY C, RADISKY, DEREK C · 2020 to 2024
$2.8M
NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA229811NCI NIH HHS R01 CA237602
6 · The paper itself

Abstract

abstractNonsteroidal anti-inflammatory agents (NSAID) are associated with modest inconsistent reductions in breast cancer risk in population-based cohorts, whereas two focused studies of patients with benign breast disease (BBD) have found lower risk with NSAID use. Given that BBD includes fibroinflammatory lesions linked to elevated breast cancer risk, we assessed whether NSAID use was associated with lower breast cancer risk among patients with BBD.Participants were postmenopausal women in the Cancer Prevention Study-II (CPS-II), a prospective study of cancer incidence and mortality, who completed follow-up surveys in 1997 with follow-up through June 30, 2015. History of BBD, NSAID use, and covariate data were updated biennially. This analysis included 23,615 patients with BBD and 36,751 patients with non-BBD, including 3,896 incident breast cancers over an average of 12.72 years of follow-up among participants. NSAID use, overall and by formulation, recency, duration, and pills per month was analyzed versus breast cancer risk overall and by BBD status using multivariable-adjusted Cox models; BBD status and NSAID use were modeled as time-dependent exposures.Patients with BBD who reported using NSAIDs experienced lower breast cancer risk (HR, 0.87; 95% CI, 0.78-0.97), with similar effects for estrogen receptor (ER)-positive breast cancers [HR, 0.85; 95% confidence interval (CI), 0.74-0.97] and ER-negative breast cancers (HR, 0.87; 95% CI, 0.59-1.29); among women without BBD, NSAID use was unrelated to risk (HR, 1.02; 95% CI, 0.92-1.13; Pinteraction = 0.04). Associations stratified by age, obesity, menopausal hormone use, and cardiovascular disease were similar.Among patients with BBD, NSAID use appears linked to lower breast cancer risk. Further studies to assess the value of NSAID use among patients with BBD are warranted. PREVENTION RELEVANCE: We examined whether NSAID use, a modifiable exposure, is associated with breast cancer risk in postmenopausal women from the Cancer Prevention Study-II with self-reported benign breast disease, an often inflammatory condition associated with higher rates of breast cancer.

Indexed as

Breast DiseasesBreast NeoplasmsFibrocystic Breast DiseaseAnti-Inflammatory Agents, Non-SteroidalFemaleHumansPostmenopauseProspective StudiesRisk FactorsAnti-Inflammatory Agents, Non-Steroidal

Identifiers

PMID36596665
PMCPMC10043807
OpenAlexW4313455979

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.